Your browser doesn't support javascript.
loading
A protease activity-based machine-learning approach as a complementary tool for conventional diagnosis of diarrhea-predominant irritable bowel syndrome.
Tanaka, Kazuki; Tanigawa, Naoki; Song, Isaiah; Komatsu, Toru; Kuriki, Yugo; Tanaka, Yukari; Fukudo, Shin; Urano, Yasuteru; Fukuda, Shinji.
Afiliação
  • Tanaka K; Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata, Japan.
  • Tanigawa N; Systems Biology Program, Graduate School of Media and Governance, Keio University, Fujisawa, Kanagawa, Japan.
  • Song I; Transborder Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan.
  • Komatsu T; Gut Environmental Design Group, Kanagawa Institute of Industrial Science and Technology, Kawasaki, Kanagawa, Japan.
  • Kuriki Y; Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata, Japan.
  • Tanaka Y; Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata, Japan.
  • Fukudo S; Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo, Tokyo, Japan.
  • Urano Y; Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo, Tokyo, Japan.
  • Fukuda S; Department of Gastroenterology, Sendai Kousei Hospital, Sendai, Miyagi, Japan.
Front Microbiol ; 14: 1179534, 2023.
Article em En | MEDLINE | ID: mdl-37485510
ABSTRACT
Irritable bowel syndrome (IBS) has no clinically accepted biomarkers even though it affects a large number of individuals worldwide. To address this lack of understanding, we evaluated peptidase activity in fecal samples from 35 patients with diarrheal IBS without symptom exacerbation (IBS-n) and 35 healthy subjects using a library of 384 fluorescent enzymatic substrate probes. IBS-n patients had high trypsin-like peptidase activity for cleavage of C-terminal lysine and arginine residues and low elastase-like activity for cleavage of C-terminal serine and glycine residues. These fluorescent probe library data, together with diagnostic machine-learning techniques, were able to accurately predict IBS-n. This approach can be used to diagnose diseases where no clinically accepted biomarkers exist, in which fecal enzyme activity is altered and also suggests that the development of new therapies targeting enzyme activities is possible.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article